MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$7,559K
Free Cash flow
-$8,091K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Prepaid expenses and other curre...
Depreciation and amortization
Effect of exchange rates on cash...
Others
Negative Cash Flow Breakdown
Net loss
Operating lease liabilities
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-10,599
-5,534
-11,103
-14,571
Share based compensation
433
556
696
-415
Impairment of long-lived assets
-
-
1,127
4,667
Impairment of goodwill
-
-
0
-
Depreciation and amortization
820
856
909
901
Non-cash lease expenses
205
210
224
1,449
Unrealized foreign exchange (gain)/loss
-441
1,714
-59
1,186
Change in contingent consideration
89
84
348
17
Non-cash interest expense
14
13
13
13
Deferred tax benefit
-23
-16
-57
-71
Profit on sale of property and equipment
32
38
-104
68
Contract asset (including related parties)
-
-
-
0
Prepaid expenses and other current assets
-1,915
-529
-1,278
-957
Research and development incentives receivable
44
149
-3,471
145
Accounts payable
-451
644
-348
-1,041
Accrued expenses and other current liabilities
104
2,586
-453
-573
Deferred income
-5
-1,046
-8
-156
Operating lease liabilities
-958
-347
-502
-504
Net cash used in operating activities
-8,091
-3,366
-4,242
-10,726
Proceeds from sale of property and equipment
61
55
2
451
Purchases of property and equipment
0
0
0
0
Net cash provided by/(used) in investing activities
61
55
2
451
Proceeds from issue of ordinary shares, net of issuance costs
-
-
0
0
Issue of shares from the exercise of stock options
0
0
0
0
Net cash provided by financing activities
0
0
0
0
Effect of exchange rates on cash, cash equivalents and restricted cash
471
-1,352
418
-1,835
Net decrease in cash, cash equivalents and restricted cash
-7,559
-4,663
-3,822
-12,110
Cash, cash equivalents and restricted cash, beginning of the period
67,189
71,852
75,674
112,400
Cash, cash equivalents and restricted cash, end of the period
59,630
67,189
71,852
75,674
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sale of
property and equipment
$61K
Effect of exchange
rates on cash, cash...
$471K
(-94.41%↓ Y/Y)
Net cash provided
by/(used) in investing...
$61K
(264.86%↑ Y/Y)
Net decrease in
cash, cash...
-$7,559K
(69.29%↑ Y/Y)
Canceled cashflow
$532K
Prepaid expenses and
other current assets
-$1,915K
(-460.64%↓ Y/Y)
Depreciation and
amortization
$820K
(-79.68%↓ Y/Y)
Unrealized foreign
exchange (gain)/loss
-$441K
(90.94%↑ Y/Y)
Share based
compensation
$433K
(131.55%↑ Y/Y)
Non-cash lease expenses
$205K
(-87.64%↓ Y/Y)
Accrued expenses and
other current...
$104K
(103.76%↑ Y/Y)
Change in contingent
consideration
$89K
(126.25%↑ Y/Y)
Non-cash interest
expense
$14K
(-44.00%↓ Y/Y)
Net cash used in
operating activities
-$8,091K
(75.49%↑ Y/Y)
Canceled cashflow
$4,021K
Net loss
-$10,599K
(74.01%↑ Y/Y)
Operating lease
liabilities
-$958K
(1.54%↑ Y/Y)
Accounts payable
-$451K
(44.53%↑ Y/Y)
Research and development
incentives receivable
$44K
(101.42%↑ Y/Y)
Profit on sale of
property and equipment
$32K
(-88.61%↓ Y/Y)
Deferred tax benefit
-$23K
(51.06%↑ Y/Y)
Deferred income
-$5K
(98.54%↑ Y/Y)
Buy us a coffee
Barinthus Biotherapeutics plc. (BRNS)
Barinthus Biotherapeutics plc. (BRNS)